despit
improv
past
sever
decad
infect
remain
signific
risk
haematolog
patient
receiv
therapi
requir
allogen
transplant
especi
hla
dispar
tcelldeplet
graft
even
higher
risk
infect
complic
due
delay
recoveri
tand
bcell
function
earli
identif
prompt
effect
treatment
paramount
improv
patient
surviv
patient
safeti
robust
adher
hand
hygien
mainten
environ
clean
disinfect
backbon
effect
prevent
program
basic
nurs
care
sound
knowledg
base
risk
present
diagnosi
treatment
improv
patient
care
infect
major
caus
mortal
morbid
haematopoiet
stem
cell
transplant
hsct
popul
due
regimenrel
toxic
improv
past
coupl
decad
especi
support
care
help
reduc
risk
develop
neutropen
fever
frequent
occurr
centr
algorithm
identifi
treat
infect
promptli
chapter
discuss
common
viral
bacteri
fungal
infect
transplant
patient
develop
mackal
et
al
display
varieti
infect
fig
may
occur
approxim
timefram
develop
aid
clinic
team
refin
direct
investig
potenti
treatment
appropri
viral
infect
spread
close
contact
infecti
secret
either
larg
particl
aerosol
formit
subsequ
selfinocul
cough
sneez
produc
aerosol
particl
viru
also
pick
contact
contamin
surfac
cytomegaloviru
cmv
diseas
seriou
potenti
complic
allogen
stem
cell
transplant
lead
lifethreaten
complic
cmv
usual
acquir
childhood
viru
present
worldwid
whilst
develop
countri
approxim
popul
seroposit
rise
almost
develop
countri
cmv
shed
intermitt
oropharynx
genitourinari
tract
immunocompet
immunosuppress
peopl
prior
allograft
serostatu
igg
patient
potenti
donor
assess
gaug
risk
zaia
et
al
mackal
et
al
cmv
belong
human
herpesviru
famili
come
subfamili
betaherpesvirina
betaherpesvirina
infect
mononuclear
cell
establish
latenc
leukocyt
reactiv
replic
slowli
cmv
abl
lie
dormant
protract
length
time
immun
cmv
complex
involv
humor
cellmedi
pathway
patient
treat
stem
cell
transplant
context
haematolog
malign
reactiv
latent
viru
either
nativ
host
leucocyt
deriv
donor
risk
reactiv
vari
depend
upon
patient
andor
donor
previou
exposur
cmv
cmv
statu
shown
follow
risk
factor
reactiv
patient
cmv
statu
indic
left
donor
cmv
statu
right
care
measur
taken
minim
risk
primari
infect
cmv
prescrib
blood
product
allograft
patient
blood
product
obtain
cmvseroneg
donor
leukocyt
deplet
cmv
serostatu
recipientdonor
previou
cmv
reactiv
time
posttranspl
increas
earli
posttranspl
period
day
tcelldeplet
transplant
condit
protocol
eg
campath
system
immunosuppress
particularli
corticosteroid
antibodi
direct
tcell
eg
atgcampath
recipi
age
increas
older
patient
graft
versu
host
diseas
gvhd
persontoperson
transmiss
low
risk
use
blood
screen
neg
cmv
meijer
et
al
cmv
occur
primari
infect
reactiv
previous
latent
viru
cmv
iggneg
patient
develop
cmv
term
primari
infect
patient
donor
known
cmv
antibodi
posit
develop
cmv
term
reactiv
diagnosi
cmv
diseas
requir
presenc
symptom
sign
compat
endorgan
damag
togeth
detect
cmv
left
untreat
asymptomat
cmv
infect
progress
cmv
diseas
import
diagnos
reactiv
earli
institut
time
treatment
therefor
regular
monitor
cmv
level
paramount
import
polymeras
chain
reaction
pcr
sensit
quantit
method
monitor
atrisk
patient
especi
earli
posttranspl
period
least
day
posttranspl
longer
system
immunosuppress
cmv
infect
commonli
affect
lung
gastrointestin
tract
eye
liver
central
nervou
system
cmv
pneumonia
seriou
complic
mortal
bone
marrow
transplant
patient
donor
cmv
statu
test
clinic
pretranspl
along
cmv
statu
donor
diseas
monitor
posttranspl
patient
seroposit
whose
graft
seroposit
must
receiv
twice
weekli
inpati
monitor
cmv
level
whole
blood
edta
sampl
pcr
weekli
outpati
set
monitor
must
continu
whilst
patient
consid
high
risk
reactiv
first
day
posttranspl
system
immunosuppress
discontinu
evid
graft
versu
host
diseas
treatment
cmv
reactiv
undertaken
follow
two
consecut
posit
cmv
pcr
level
greater
limit
sensit
copiesml
one
result
greater
copiesml
depend
local
polici
treatment
also
initi
regardless
pcr
sign
organspecif
diseas
identifi
centr
may
adopt
polici
preemptiv
treatment
pleas
refer
institut
guidelin
advic
treatment
regimen
often
undertaken
inpati
case
firstlin
therapi
intraven
ganciclovir
mgkg
twice
daili
minimum
week
secondlin
treatment
may
given
signific
ganciclovirrel
bone
marrow
suppress
neutrophil
count
less
treatment
failur
rise
viral
level
evid
viral
resist
least
week
treatment
secondand
thirdlin
treatment
foscarnet
mgkg
twice
daili
cidofovir
mg
kg
weekli
week
follow
fortnightli
neg
foscarnet
may
adopt
firstlin
treatment
patient
reactiv
within
first
month
transplant
blood
count
fulli
recov
less
myelotox
ganciclovir
howev
renal
complic
regular
electrolyt
replac
often
requir
similarli
cidofovir
lead
renal
impair
urin
sampl
test
prior
infus
presenc
protein
proteinuria
greater
dipstick
renal
function
deterior
pleas
refer
hospitalunit
guidelin
cidofovir
given
asymptomat
patient
viral
level
respons
treatment
fit
discharg
oral
therapi
valganciclovir
may
use
outpati
use
valganciclovir
asymptomat
reactiv
usual
confin
lowlevel
reactiv
around
log
detail
instruct
consult
summari
product
inform
websit
address
http
emcmedicinesorgukemcassetsc
htmldisplaydocasp
http
emcmedicinesorgukemcassetsc
htmldisplaydocasp
access
normal
dose
ganciclovir
mgkg
given
everi
h
intraven
infus
ml
normal
salin
hour
round
dose
nearest
mg
drug
irrit
alkalin
may
caus
chemic
phlebiti
care
taken
observ
cannula
ensur
function
well
prior
use
normal
dose
valganciclovir
mg
taken
everi
h
oral
valganciclovir
oral
prodrug
ganciclovir
consider
made
use
ganciclovir
ganciclovir
valganciclovir
use
caution
patient
impair
renal
function
addit
toxic
patient
take
nephrotox
drug
eg
ciclosporin
amphotericin
b
patient
dose
adjust
must
given
use
togeth
imipenemcilastatin
due
increas
risk
convuls
ganciclovir
valganciclovir
treatment
commonli
result
cytopenia
extrem
caution
appli
use
patient
impair
bone
marrow
function
neutrophil
l
platelet
l
drug
contraind
sever
impair
bone
marrow
function
neutrophil
l
platelet
l
dose
adjust
must
made
degre
renal
impair
creatinin
clearanc
must
calcul
use
cockcroftgault
equat
dose
decis
anoth
formula
institut
teratogen
shown
anim
model
therefor
care
use
handl
drug
administ
pregnant
staff
bone
marrow
suppress
common
blood
count
monitor
daili
therapi
visual
prior
infus
patient
signific
cytopenia
treat
haemopoiet
growth
factor
andor
discontinu
therapi
growth
factor
support
avail
clinic
safe
patient
develop
cytopenia
must
discuss
treat
consult
clinic
decis
made
regard
continu
therapi
gastrointestin
toxic
common
nausea
vomit
diarrhoea
record
drug
eg
ciclosporin
amphotericin
b
mmf
may
also
potenti
toxic
ganciclovir
detail
consult
smpc
email
link
discuss
pharmacist
lead
clinician
detail
instruct
consult
summari
product
characterist
http
access
normal
dose
mgkg
given
everi
h
intraven
infus
drug
irrit
alkalin
caus
chemic
phlebiti
therefor
must
dilut
administ
via
peripher
vein
undilut
solut
mg
ml
may
use
administ
via
central
venou
cathet
foscarnet
use
caution
patient
impair
renal
function
addit
toxic
patient
take
nephrotox
drug
eg
ciclosporin
amphotericin
b
minim
risk
renal
impair
addit
ml
fluid
salin
dextros
coadminist
dose
foscarnet
nephrotox
major
side
effect
patient
show
signific
declin
renal
function
electrolyt
disturb
occur
frequent
low
magnesium
calcium
phosphat
potassium
commonli
requir
regular
monitor
least
daili
whilst
treatment
follow
therapi
hypocalcaemia
complic
use
foscarnet
implic
patient
develop
seizur
therapi
local
irrit
vein
may
occur
advis
central
venou
access
use
possibl
togeth
mainten
good
hydrat
diuresi
treatment
local
ulcer
genit
area
may
also
occur
men
women
patient
inform
start
treatment
ask
vigil
inform
staff
occur
strict
hygien
advis
reduc
risk
skin
ulcer
gastrointestin
toxic
common
nausea
vomit
diarrhoea
cn
toxic
infrequ
patient
may
suffer
headach
dizzi
anorexia
alter
mental
state
haematolog
toxic
also
common
mainli
result
anaemia
leucopenia
less
common
whilst
thrombocytopenia
occur
infrequ
detail
instruct
consult
summari
product
characterist
h
p
w
w
w
h
r
g
v
u
k
p
c
p
l
prodnamecidofovirtillom
mgml
concentr
solut
infus
subsnamecidofovir
dihydr
ate
pageidsecondlevel
access
normal
dose
mgkg
given
weekli
intraven
infus
two
dose
induct
given
twice
weekli
mainten
mainten
treatment
start
week
complet
induct
therapi
continu
clearanc
viru
often
first
dose
given
inpati
dose
given
outpati
well
staf
appropri
train
cidofovir
markedli
nephrotox
damag
occur
often
irrevers
cidofovir
contraind
patient
preexist
renal
dysfunct
renal
toxic
occur
frequent
treatment
renal
function
must
monitor
close
deterior
like
necessit
discontinu
therapi
addit
toxic
patient
take
nephrotox
drug
eg
ciclosporin
amphotericin
b
minim
renal
toxic
hydrat
probenecid
must
administ
dose
cidofovir
patient
hypersensit
probenecid
sulphacontain
drug
cidofovir
like
contraind
case
must
discuss
treat
consult
initi
therapi
cidofovir
also
frequent
caus
nondosedepend
neutropenia
although
may
resolv
spontan
whilst
continu
treatment
dose
interrupt
mandatori
patient
develop
neutropenia
although
risk
benefit
continu
treatment
patient
must
discuss
treat
consult
transplant
physician
renal
dysfunct
major
doselimit
toxic
may
irrevers
eighti
percent
patient
develop
proteinuria
due
tubular
dysfunct
whilst
therapi
gastrointestin
toxic
common
nausea
vomit
haematolog
toxic
common
mainli
neutropenia
alopecia
uveiti
fever
also
frequent
observ
treatment
cidofovir
resolv
discontinu
current
sever
new
emerg
drug
treatment
cmv
although
far
shown
superior
four
drug
follow
phase
clinic
trial
newer
therapi
includ
maribavir
brincidofovir
letermovir
anoth
option
patient
difficult
treat
could
use
cmvspecif
ctl
unfortun
expens
difficult
obtain
epsteinbarr
viru
ebv
latent
herpesviru
thought
infect
much
adult
popul
age
year
envelop
doublestrand
dna
viru
human
herpesviru
primari
infect
ebv
usual
result
mild
selflimit
ill
oropharynx
childhood
clinic
syndrom
infecti
mononucleosi
adult
often
asymptomat
primari
infect
immunocompet
individu
mount
vigor
respons
initi
infect
clear
linear
ebv
genom
becom
circular
form
episom
infect
b
cell
becom
establish
latent
infect
await
reactiv
relev
implic
clinic
approach
antivir
agent
ganciclovir
inhibit
replic
linear
ebvdna
ineffect
episom
dna
drug
therefor
fail
prevent
bcell
prolifer
clinic
use
treatment
plan
rasch
et
al
epsteinbarr
viru
posttranspl
lymphoprolif
diseas
ebvptld
result
outgrowth
ebvinfect
b
cell
normal
control
effect
ebvspecif
cytotox
tcell
respons
occur
immunocompromis
host
deeg
soci
heslop
ptld
classifi
either
earlyonset
lesion
develop
within
year
late
onset
occur
greater
year
posttranspl
ibrahim
naresh
clinic
manifest
ptld
vari
wide
may
includ
nonspecif
symptom
fever
malais
sweat
weight
loss
case
obviou
enlarg
lymphoid
tissu
ibrahim
naresh
posttranspl
lymphoprolif
diseas
ptld
rare
potenti
lifethreaten
diseas
incid
mortal
prerituximab
era
landgren
et
al
defin
lymphoid
prolifer
lymphoma
develop
consequ
immunosuppress
recipi
solid
organ
bone
marrow
transplant
immunosuppress
requir
preserv
graft
function
posttranspl
lead
impair
tcell
immun
allow
uncontrol
prolifer
ebvinfect
b
cell
result
monoclon
polyclon
plasmacyt
hyperplasia
bcell
hyperplasia
bcell
lymphoma
immunoblast
lymphoma
immun
surveil
impair
balanc
latent
infect
bcell
prolifer
ebvspecif
tcell
respons
disrupt
lead
infect
b
cell
develop
ptld
heslop
earli
detect
ebv
viral
load
polymeras
chain
reaction
pcr
whole
blood
wide
accept
prefer
method
monitor
patient
commenc
day
cell
infus
viral
level
monitor
weekli
month
longer
gvhd
immunosuppress
greater
risk
recipi
tcelldeplet
hsct
hla
mismatch
patient
condit
antithymocyt
globulin
landgren
et
al
risk
factor
identifi
predict
develop
ptld
includ
recipi
pretranspl
ebv
seroneg
donor
ebv
seroposit
styczynski
et
al
presum
ebv
transmit
donor
recipi
via
graft
time
consider
immunosuppress
recipi
patient
develop
primari
ebv
infect
unrel
donor
ebv
statu
therefor
advis
possibl
choos
seroneg
donor
one
avail
reactiv
common
alway
lead
endorgan
diseas
requir
treatment
styczynski
et
al
cohen
review
case
ptld
literatur
involv
renal
cardiac
heartlung
liver
bone
marrow
transplant
allogen
bone
marrow
transplantationrel
ptld
incid
much
higher
patient
receiv
mismatch
tcelldeplet
bone
marrow
patient
receiv
antitcel
monoclon
antibodi
graft
versu
host
diseas
mean
time
interv
transplant
diagnosi
ptld
month
major
month
patholog
diagnosi
ptld
base
classif
includ
four
main
categori
basi
uk
bcsh
guidelin
show
featur
biopsi
infecti
mononucleosi
plasmacyt
hyperplasia
first
sign
spectrum
ptld
diagnosi
compris
smalland
mediums
lymphocyt
reedsternberglik
cell
underli
cell
structur
destroy
may
show
malign
featur
compris
larg
lymphocyt
plasma
cell
uniform
appear
b
cell
clonal
abnorm
rare
form
ptld
usual
found
renal
transplant
patient
swerdlow
et
al
practic
clear
separ
differ
subtyp
alway
possibl
earli
lesion
polymorph
ptld
monomorph
ptld
probabl
repres
spectrum
diseas
parker
et
al
ptld
endorgan
diseas
ebv
detect
organ
biopsi
invas
procedur
test
appropri
sensit
specif
togeth
symptom
andor
sign
affect
organ
earli
diagnosi
import
treatment
initi
promptli
exact
copi
log
number
commenc
therapi
yet
fulli
establish
action
blood
test
alon
indic
parallel
clinic
symptom
fever
lymphadenopathi
imag
studi
heslop
whether
ptld
present
local
dissemin
diseas
tumour
aggress
rapidli
progress
often
fatal
clinic
present
variabl
includ
fever
lymphadenopathi
gastrointestin
symptom
infecti
mononucleosislik
syndrom
fulmin
pulmonari
symptom
cn
symptom
weight
loss
patient
may
report
fever
weight
loss
anorexia
lethargi
sore
throat
swollen
gland
diarrhoea
abdomin
pain
short
breath
neurolog
symptom
symptom
initi
would
suggest
diagnosi
ptld
cn
involv
particular
concern
offer
dismal
prognosi
deeg
soci
common
site
involv
lymph
node
liver
lung
kidney
bone
marrow
small
intestin
spleen
cn
larg
bowel
tonsil
salivari
gland
tcell
lymphoprolif
disord
associ
ebv
infect
tend
occur
extranod
site
reactiv
usual
occur
first
month
year
posttranspl
predominantli
deriv
donor
b
cell
reconstitut
ebvspecif
cytotox
tlymphocyt
respons
occur
later
patient
still
heavili
immunosuppress
eg
take
ciclosporin
kuriyama
et
al
withdraw
immunosuppress
first
instanc
patient
still
posit
treatment
rituximab
monoclon
antibodi
ct
scan
possibl
biopsi
taken
standard
therapi
transplant
ptld
remov
immunosuppress
restor
immun
respons
usual
effect
treat
develop
ptld
close
transplant
date
due
profound
immunosuppress
state
regener
immun
system
abl
recov
fast
enough
erad
malign
cell
also
carri
risk
graft
reject
significantli
away
transplant
may
reduc
ebv
load
remov
immunosuppress
alon
rituximab
shown
improv
outcom
initi
earli
target
bcellspecif
surfac
antigen
present
ebvtransform
malign
cell
rituximab
chimer
murin
human
monoclon
antibodi
cell
express
malign
cell
normal
b
cell
destroy
patient
alreadi
immunocompromis
may
lead
viral
infect
effect
rituximab
bcell
compart
month
follow
treatment
therefor
use
caution
strict
surveil
specialist
centr
failur
respond
singleag
rituximab
lead
option
chemotherapi
form
chop
cyclophosphamid
doxorubicin
vincristin
prednisolon
addit
option
adopt
tcell
therapi
still
unavail
mani
centr
seri
studi
suggest
may
offer
respons
standard
rituximab
fail
ebvspecif
cytotox
cell
ctl
aim
select
restor
impair
immun
function
adopt
transfer
ebvspecif
cytotox
cell
ctl
gener
use
ebvinfect
lymphoblast
cell
line
suffici
stimul
donorderiv
cell
expand
period
give
patient
timeconsum
process
one
patient
often
wait
quicker
process
rapidli
gener
ctl
overnight
stimul
donor
mononuclear
blood
cell
ebvspecif
peptid
select
agspecif
cell
ifngamma
surfac
captur
assay
subsequ
immunomagnet
select
develop
although
wide
avail
associ
high
risk
develop
acut
chronic
gvhd
post
infus
risk
benefit
discuss
patient
rasch
et
al
rituximab
given
iv
infus
vesic
initi
given
slowli
reduc
risk
reaction
subsequ
cycl
given
quicker
toler
reaction
rituximab
thought
mediat
cytokin
releas
normal
malign
b
cell
common
advers
event
ae
rituximab
includ
infus
reaction
major
mild
moder
grade
natur
seventyseven
percent
grade
infus
reaction
occur
first
infus
incid
decreas
subsequ
infus
infus
reaction
gener
resolv
slow
interrupt
infus
support
care
incid
grade
infusionrel
event
patient
report
first
infus
rituximab
major
sever
reaction
occur
approxim
min
start
first
infus
human
herpesviru
ubiquit
viru
popul
age
year
seroposit
easili
pass
person
person
via
saliva
usual
latent
commonli
reactiv
approx
postallogen
stem
cell
transplant
patient
increas
risk
hla
mismatch
corticosteroid
therapi
gvhd
highest
umbil
cord
ucbt
allograft
incid
compar
bm
pbsc
recipi
postul
higher
incid
due
lack
memori
cell
ucbt
present
adult
donor
may
associ
develop
enceph
patient
also
report
pneumonia
zerr
et
al
divid
two
group
variant
b
primari
infect
caus
exanthema
subitum
roseola
infantum
infant
whilst
role
diseas
yet
fulli
explor
typic
reactiv
earlier
cytomegaloviru
post
allograft
evid
relationship
posit
enceph
conclus
especi
often
asymptomat
clinic
patient
present
week
post
allograft
delirium
amnesia
confus
ataxia
seizur
transplant
process
cite
zerr
et
al
caus
delay
engraft
platelet
requir
becom
posit
memori
loss
cite
common
featur
develop
confus
final
unconsci
may
accompani
syndrom
inappropri
antidiuret
hormon
siadh
magnet
reson
imag
mri
head
hyperintens
lesion
note
refer
posttranspl
acut
limbic
enceph
pale
upon
examin
cerebrospin
fluid
csf
dna
observ
confirm
diagnosi
made
gold
standard
would
tissu
biopsi
imposs
acut
unwel
posttranspl
patient
therefor
accept
approach
pcr
test
csf
exclus
caus
patient
symptom
foscarnet
ganciclovir
recommend
treatment
start
soon
possibl
follow
symptom
suggest
ogata
et
al
pneumocysti
jirovecii
pcp
atyp
fungu
caus
sever
pneumonia
immunocompromis
patient
recogn
protozoan
initi
reclassifi
fungu
pneumocysti
propag
cultur
treatment
option
exist
pcp
pneumonia
ubiquit
almost
univers
seroposit
year
age
thoma
limper
accept
belief
contract
pcp
reactiv
latent
viru
howev
evid
suggest
pcp
may
occur
follow
recent
infect
may
also
transmit
person
person
mani
hospit
polici
mandat
isol
pragmat
approach
often
taken
hsct
recipi
avoid
exposur
proven
pcp
geabanacloch
et
al
recommend
allograft
patient
adequ
cover
prophylaxi
pcp
least
month
year
immunosuppress
combin
trimethoprimsulfamethoxazol
tmpsmx
reduc
incid
infect
approxim
castro
et
al
prophylaxi
usual
start
point
engraft
upon
discharg
tmpsmx
caus
engraft
delay
effect
firstlin
prophylaxi
combin
trimethoprimsulfamethoxazol
given
varieti
dose
depend
upon
local
polici
patient
develop
sensit
drug
altern
pentamidin
nebul
atovaquon
oral
dapson
dapson
use
glucos
dehydrogenas
defici
rule
highli
preval
african
asian
oceanian
southern
european
popul
defici
may
develop
acut
haemolyt
anaemia
nebul
pentamidin
caus
bronchospasm
patient
need
inform
prior
inhal
atovaquon
gener
well
toler
poorli
absorb
unless
taken
high
fat
diet
patient
immedi
posttranspl
set
may
struggl
especi
gi
gvhd
issu
geabanacloch
et
al
pcp
present
symptom
subtl
onset
dyspnoea
lowgrad
temperatur
nonproduct
cough
examin
chest
clear
auscult
howev
may
rapidli
chang
onset
hypoxia
requir
admiss
critic
care
unit
imag
chest
xray
reveal
bilater
perihilar
interstiti
infiltr
becom
increasingli
homogen
diffus
diseas
progress
comput
tomographi
ct
scan
show
extens
groundglass
attenu
cystic
lesion
thoma
limper
patient
mortal
associ
develop
pcp
prompt
diagnosi
treatment
warrant
adher
prophylact
cover
due
difficulti
cultur
sampl
diagnosi
pcp
made
microscop
examin
sputum
bronchoalveolar
fluid
polymeras
chain
reaction
pcr
pcp
pneumonia
suspect
treatment
trimethoprimsulfamethoxazol
addit
system
steroid
reduc
inflammatori
lung
process
intoler
trimethoprimsulfamethoxazol
atovaquon
combin
clindamycin
primaquin
licenc
use
chen
et
al
varicella
zoster
viru
vzv
infect
chickenpox
usual
childhood
diseas
transmiss
either
inhal
respiratori
secret
direct
physic
contact
follow
exposur
viru
remain
latent
dorsal
root
ganglion
reactiv
refer
shingl
herp
zoster
herp
zoster
group
pain
vesicular
lesion
affect
sever
dermatom
immunocompet
peopl
set
allogen
stem
cell
transplant
vzv
carri
major
risk
morbid
mortal
patient
clinic
appar
infect
relat
reactiv
latent
viru
howev
use
aciclovir
number
decreas
thomson
et
al
complic
postherpet
neuralgia
skin
scar
bacteri
superad
infect
factor
morbid
steer
et
al
boeckh
et
al
stem
cell
transplant
patient
receiv
prophylaxi
vzv
oral
aciclovir
valaciclovir
month
year
accord
local
polici
immunosuppress
discontinu
kanda
et
al
transmiss
vzv
difficult
prevent
period
prior
symptom
individu
contagi
h
appear
rash
incub
period
vari
day
individu
remain
contagi
vesicl
crust
immunocompromis
patient
contact
individu
vzv
infect
varicella
hz
signific
risk
develop
varicella
requir
prompt
action
transplant
team
styczynski
et
al
hsct
probabl
destroy
previou
immun
vzv
immun
famili
contact
especi
children
advis
reduc
risk
vzv
infect
occur
prophylaxi
stop
month
peak
incid
around
month
spread
month
usual
occur
within
week
cessat
oral
prophylaxi
steer
et
al
risk
factor
includ
unrel
donor
myeloabl
condit
graft
versu
host
diseas
gvhd
use
system
corticosteroid
pain
back
abdomen
distens
rise
alt
seen
approx
ten
patient
prior
develop
rash
rash
may
spread
dermatom
patient
viscer
dissemin
difficult
treat
best
method
diagnos
vzv
polymeras
chain
reaction
pcr
test
blood
glass
slide
touch
vesicl
dna
highli
specif
sensit
treatment
expos
healthi
individu
vzv
infect
advis
depend
upon
serostatu
recipi
avail
drug
patient
seroneg
less
year
post
allograft
activ
chronic
gvhd
take
immunosuppress
medic
intraven
varicella
zoster
immunoglobulin
vzig
passiv
immun
medic
unavail
highdos
aciclovir
valaciclovir
famciclovir
nucleosid
analogu
interfer
viral
thymidin
kinas
activ
employ
post
treatment
vzv
advis
restart
prophylact
aciclovir
previous
discontinu
length
time
prophylaxi
continu
guid
local
polici
may
rang
year
lifelong
adenoviru
adv
ubiquit
nonenvelop
doublestrand
dna
viru
current
serotyp
divid
six
subgroup
af
la
rosa
et
al
adenoviru
preval
children
becom
preval
adult
transplant
popul
adenoviru
spread
aerosol
faecalor
rout
approx
children
age
year
old
seroposit
risk
factor
includ
mismatch
unrel
donor
acut
graft
versu
host
diseas
agvhd
isol
adv
multipl
site
ljungman
et
al
healthi
individu
infect
selflimit
caus
conjunct
upper
respiratori
tract
urinari
tract
gastrointestin
infect
remain
latent
lymphocyt
post
exposur
chakrabarti
et
al
report
incid
adv
allogen
stem
cell
transplant
virallik
symptom
usual
full
screen
virolog
request
includ
adv
sampl
taken
nasopharyng
rectal
corneal
secret
urin
unfix
biopsi
tissu
examin
pcr
assess
viral
load
similar
viral
reactiv
cmv
ebv
low
level
adv
infect
carri
high
mortal
howev
patient
develop
invas
diseas
adv
coliti
signific
mortal
robin
et
al
cidofovir
firstlin
treatment
monophosph
nucleotid
analogu
cytosin
cidofovir
inhibit
viral
dna
polymeras
low
bioavail
drug
excret
urin
patient
requir
hyperhydr
oral
probenecid
pre
post
cidofovir
protect
nephron
hepat
b
viru
hbv
dna
viru
classifi
hepadna
viru
famili
patient
infect
hbv
prior
transplant
higher
risk
hbv
reactiv
year
hsct
transplant
activ
immun
donor
earli
posttranspl
vaccin
recipi
suggest
avoid
hbv
reactiv
donor
optim
receiv
one
immun
rather
high
ag
dose
highli
immunogen
vaccin
lindemann
et
al
use
chemotherapi
immunosuppress
reactiv
latent
hepat
b
hbv
infect
reactiv
contribut
liverrel
morbid
mortal
occur
patient
especi
condit
regimen
contain
alemtuzumab
transplant
hbvneg
patient
stem
cell
infect
donor
hbsag
posit
associ
high
risk
transmiss
patient
develop
chronic
hepat
b
donor
activ
hbv
dna
detect
receiv
possibl
antivir
treatment
ullmann
et
al
posttranspl
hbv
infect
aris
differ
way
patient
may
activ
hbv
hbsag
posit
prior
transplant
reactiv
latent
hbv
infect
hbsag
neg
infect
may
also
occur
transplant
process
infect
hsc
donor
rare
infect
blood
product
hbv
dna
titer
may
rise
high
level
particularli
patient
receiv
corticosteroid
time
immun
reconstitut
reduct
immunosuppress
drug
flare
given
rise
serum
aspart
aminotransferas
ast
alanin
aminotransferas
alt
level
anoth
clinic
symptom
jaundic
fulmin
liver
failur
result
hbv
liverrel
mortal
lau
et
al
lamivudin
mgday
first
choic
antivir
therapi
treatment
continu
least
month
follow
discontinu
immunosuppress
drug
allogen
haematopoiet
cell
transplant
patient
sever
studi
literatur
describ
prevent
hbv
reactiv
set
immunosuppress
hbv
reactiv
variabl
report
alt
elev
upper
limit
normal
increas
baselin
patient
undergo
hsct
haematolog
malign
atrisk
popul
prolong
immunosuppress
follow
condit
chemotherapi
nucleosid
analogu
antivir
drug
lamivudin
adefovir
telbivudin
entecavir
tenofovir
may
potenti
use
prevent
hbv
reactiv
patient
major
report
describ
use
lamivudin
entecavir
drug
appear
reduc
incid
hbv
reactiv
howev
entecavir
potenti
tenofovir
may
superior
lamivudin
potent
viral
suppress
lower
risk
antivir
resist
prophylaxi
hbv
reactiv
antivir
nucleosid
analogu
commenc
suscept
individu
initi
chemotherapi
order
lessen
risk
hbv
reactiv
associ
advers
clinic
outcom
pattullo
hepat
c
viru
hcv
doublestrand
rna
viru
classifi
within
flavivirida
six
major
genotyp
identifi
respons
sever
system
complic
extrahepat
manifest
includ
vascul
fatigu
cryoglobulinemia
autoimmun
disord
hcv
replic
significantli
increas
immunosuppress
may
caus
direct
cytopath
effect
infect
cell
identif
pretranspl
hcv
infect
appear
clinic
relev
infect
hcv
indic
independ
risk
factor
posttranspl
venoocclus
diseas
vod
liver
reactiv
chronic
hcv
infect
taper
immunosuppress
therapi
sometim
lead
fulmin
hepat
failur
locasciulli
et
al
hcv
infect
respons
hepat
extrahepat
manifest
year
post
hsct
hcv
infect
cours
increas
risk
fatal
sinusoid
obstruct
syndrom
later
hepat
inflamm
occur
month
hct
coincid
immun
reconstitut
interrupt
immunosuppress
medic
symptom
liver
decompens
among
patient
cirrhosi
time
transplant
describ
literatur
rare
fatal
fibros
cholestat
hcv
occur
day
recipi
receiv
mycophenol
mofetil
torr
et
al
hcv
infect
associ
high
risk
sever
complic
includ
acceler
liver
diseas
progress
acut
hcv
exacerb
viral
reactiv
last
two
common
associ
increas
liverrel
mortal
rate
chang
hsct
care
kyvernitaki
et
al
report
case
sever
hcv
reactiv
occur
earli
day
hct
elev
alt
bilirubin
level
liver
biopsi
reveal
chronic
portal
inflamm
bile
duct
injuri
moder
cholestasi
oliv
et
al
hcv
advers
impact
platelet
recoveri
nonrelaps
mortal
overal
surviv
sinusoid
obstruct
syndrom
so
liver
graft
versu
host
diseas
gvhd
hepat
problem
like
sever
fatal
recipi
hcv
pretranspl
hcv
infect
associ
lower
rate
platelet
recoveri
excess
bacteri
infect
hct
recipi
hcv
infect
report
find
suggest
defenc
mechan
bacteri
infect
impair
recipi
hcv
nakason
et
al
hsct
recipi
hcv
infect
evalu
hcv
therapi
start
condit
therapi
whenev
possibl
hcvinfect
hsct
candid
commenc
complet
hcv
therapi
transplant
oncolog
imper
move
quickli
transplant
therapi
directact
antivir
agent
daa
abl
clear
extrahepat
hcv
donor
quickli
interferon
ribavirin
treatment
posttranspl
hcv
infect
must
urgent
consider
patient
fibros
cholestat
hcv
patient
cirrhosi
whose
condit
deterior
patient
underw
hsct
hcvrelat
lymphoprolif
disord
hcv
therapi
initi
treatment
interrupt
recommend
associ
increas
risk
treatment
failur
altern
prehsct
therapi
hcv
treat
hct
use
daa
follow
immun
reconstitut
longterm
hcvinfect
hsct
survivor
offer
daa
therapi
hcv
therapi
undertaken
provid
experienc
manag
hcv
hsct
mani
combin
daa
depend
hcv
genotyp
commonli
use
daa
includ
daclatasvir
sofosbuvir
ledipasvir
ombitasvir
paritaprevir
ritonavir
dasabuvir
simeprivir
ribavirin
choic
regimen
individu
basi
patientspecif
data
take
consider
potenti
drug
interact
tacrolimu
sirolimu
ciclosporin
torr
et
al
vaccin
hcv
exist
howev
prevent
complic
coinfect
peopl
hepat
c
vaccin
hepat
b
standard
precaut
recommend
care
treatment
patient
regardless
perceiv
confirm
infecti
statu
handl
blood
bodi
fluid
secret
excret
nonintact
skin
mucou
membran
ashm
hcvinfect
donor
evalu
hcv
therapi
treat
cell
harvest
order
prevent
transmiss
hcv
uninfect
recipi
torr
et
al
hepat
e
hepat
e
viru
hev
singlestrand
nonenvelop
rna
viru
discov
investig
outbreak
unexplain
hepat
russian
soldier
afghanistan
area
poor
sanit
hev
spread
orofaec
human
usual
via
contamin
water
develop
countri
hev
hev
transmit
anim
reservoir
hev
antibodi
found
pig
farmer
slaughterhous
worker
veterinarian
farm
labour
western
europ
food
chain
main
sourc
infect
hev
transmit
consumpt
contamin
anim
meat
undercook
pig
liver
persontoperson
transmiss
uncommon
although
nosocomi
parenter
transmiss
haemophiliac
haemodialysi
patient
report
marano
et
al
common
symptom
hev
jaundic
follow
extrahepat
manifest
acut
chronic
hepat
e
involv
follow
system
organ
dalton
et
al
tabl
incub
period
week
genotyp
develop
hev
infect
sourc
infect
human
mostli
faecalor
rout
via
infect
water
outbreak
occur
time
floodingmonsoon
involv
thousand
case
symptom
hev
progress
fever
nausea
abdomin
pain
vomit
numer
studi
report
autochthon
hev
problem
across
europ
infect
predilect
middleag
elderli
male
mean
age
year
larg
outbreak
occur
case
sporad
sourc
infect
remain
uncertain
case
develop
countri
distinguish
acut
chronic
hepat
e
acut
hev
mostli
caus
genotyp
jaundic
occur
patient
clinic
manifest
hepat
e
develop
countri
hev
infect
may
misdiagnos
druginduc
liver
injuri
dili
respons
extrahepat
disord
neurolog
disord
kidney
injuri
acut
pancreat
associ
hev
haematolog
disord
thrombocytopenia
aplast
anaemia
studi
assess
preval
incid
hev
infect
among
haematolog
patient
receiv
chemotherapi
small
number
found
chronic
hev
infect
includ
patient
untreat
hairi
cell
leukaemia
patient
idiopath
lymphopenia
patient
treat
lymphoma
chronic
myelomonocyt
leukaemia
bcell
chronic
lymphocyt
leukaemia
hev
rna
found
stem
cell
transplant
patient
develop
chronic
hepat
kamar
et
al
one
case
chronic
hev
infect
follow
allogen
haematopoiet
stem
cell
transplant
report
differenti
diagnosi
graft
versu
host
diseas
betting
et
al
haematolog
patient
pegyl
interferon
alon
ribavirin
alon
month
use
kamar
et
al
immunocompromis
patient
screen
hev
antibodi
rna
prior
transplant
also
posttransplant
episod
liver
enzym
abnorm
immunocompet
patient
adequ
cook
procedur
porcin
boardeer
meat
use
prevent
hev
diseas
de
keukeleir
reynder
list
common
viru
patient
develop
transplant
infect
prevent
antimicrobi
stewardship
antimicrobi
prophylaxi
essenti
control
manag
mdro
hand
hygien
environment
cleaningdisinfect
isol
surveil
inde
backbon
effect
prevent
program
trubiano
et
al
world
health
organ
declar
antimicrobi
resist
worldwid
threat
requir
urgent
action
applic
contact
precaut
cp
requir
gown
glove
worn
enter
patient
room
remov
leav
dedic
equip
stethoscop
blood
pressur
cuff
remain
patient
room
use
patient
cp
may
includ
singleroom
isol
entir
isol
ward
cohort
group
patient
without
design
staff
aim
cp
prevent
transmiss
epidemiolog
import
pathogen
colon
infect
patient
direct
patient
healthcar
personnel
indirect
surfac
roommat
patient
environ
contact
addit
hand
hygien
appropri
cp
measur
decreas
risk
mdro
transmiss
current
controversi
remain
whether
patient
colon
rather
infect
mdro
subject
isol
anoth
issu
impact
cp
patient
wellb
healthcar
worker
care
patient
contact
isol
enter
room
less
frequent
significantli
less
direct
contact
patient
express
greater
dissatisfact
treatment
less
document
care
landel
et
al
review
cohen
et
al
report
cp
repres
statist
signific
improv
mdro
infect
control
five
six
review
studi
find
signific
associ
cp
reduct
mdro
transmiss
cohen
et
al
gramposit
gram
pathogen
caus
signific
morbid
mortal
bone
marrow
transplant
recipi
enterococci
gramposit
aerob
facult
anaerob
seen
microscop
singl
pair
short
chain
part
normal
flora
gastrointestin
tract
transplant
recipi
enterococc
infect
usual
nosocomi
occur
gener
invas
infect
immedi
posttranspl
period
mostli
consequ
endogen
gramposit
transloc
enterococci
vre
vre
also
known
glycopeptideresist
enterococci
increasingli
caus
outbreak
haematolog
unit
mani
transplant
centr
vre
predomin
organ
caus
preengraft
bacteraemia
among
hsct
recipi
evid
associ
act
contact
precaut
surveil
test
incid
vre
bacteraemia
start
stagger
vre
strongli
associ
colon
pressur
strategi
reduc
vre
burden
colon
patient
may
reduc
vre
transmiss
infect
control
effort
includ
contact
precaut
need
activ
surveil
test
guid
local
epidemiolog
howev
almyroudi
et
al
report
discontinu
system
surveil
contact
precaut
vre
impact
incid
vre
faecium
bacteraemia
patient
haematolog
malign
studi
incid
vre
bacteraemia
remain
stabl
discontinu
surveil
contact
precaut
furthermor
contact
isol
associ
medic
error
reduc
visit
physician
nurs
safeti
concern
increas
fall
bedsor
anxieti
depress
among
patient
signific
increas
cost
care
almyroudi
et
al
dykewicz
kaplan
streptococcu
viridan
facult
anaerob
gramposit
cocci
part
normal
microflora
found
mainli
oral
caviti
also
upper
respiratori
gastrointestin
femal
genit
tract
septicaemia
common
manifest
bone
marrow
transplant
bmt
recipi
ihendyan
et
al
lessen
risk
oral
sourc
infect
follow
hsct
dental
treatment
oral
hygien
instruct
given
week
hsct
requir
streptococcu
pneumonia
gramposit
diplococcu
caus
signific
morbid
mortal
age
group
wherein
children
elderli
immunocompromis
patient
especi
vulner
pneumococc
infect
may
occur
hospit
transplant
procedur
commonli
occur
communityacquir
infect
month
year
follow
transplant
mening
fulmin
sepsi
last
decad
multidrugresist
mdr
gramneg
gram
pathogen
implic
sever
healthcareassoci
infect
occurr
increas
steadili
emerg
problem
carbapenemaseproduc
enterobacteriacea
becom
major
healthcar
threat
associ
mortal
also
haematolog
popul
recommend
strategi
prevent
healthcareassoci
transmiss
gramneg
bacteria
prompt
laboratorybas
identif
adher
contact
precaut
strict
hand
hygien
expens
approach
includ
dedic
equip
staff
especi
patient
mdr
respiratori
tract
cohort
patient
specif
hospit
area
effect
also
disrupt
final
integr
antimicrobi
stewardship
effort
base
domin
mdr
organ
may
help
prevent
futur
problem
escmid
guidelin
manag
infect
control
measur
reduc
transmiss
multidrugresist
gramneg
bacteria
hospit
patient
tacconelli
et
al
summar
import
adher
hand
hygien
wear
contact
precaut
use
dispos
singleus
patientded
care
equip
perform
activ
screen
cultur
well
role
environment
clean
antimicrobi
stewardship
role
infrastructur
educ
reduc
spread
enterobacteriacea
facult
anaerob
intestin
colon
enterobacteriacea
encompass
larg
heterogen
famili
gramneg
bacteria
divid
lactos
ferment
escherichia
coli
citrobact
klebsiella
spp
enterobact
spp
nonlactos
ferment
salmonella
shigella
proteu
yersinia
k
pneumonia
encount
saprophyt
human
mammal
colon
gastrointestin
tract
skin
nasopharynx
past
seen
import
caus
agent
communityacquir
infect
includ
sever
form
pneumonia
earli
infect
caus
k
pneumonia
becam
lead
caus
nosocomi
infect
high
carriag
rate
record
patient
nasopharynx
hand
well
gastrointestin
tract
k
pneumonia
consider
effici
colon
enhanc
acquir
resist
antibiot
enabl
persist
spread
rapidli
healthcar
set
k
pneumonia
notori
collector
multidrug
resist
mechan
carbapenemas
encod
transmiss
plasmid
clinic
import
carbapenemas
enterobacteriacea
class
enzym
kpc
type
zincdepend
class
b
repres
mainli
vim
imp
ndm
type
plasmidexpress
class
carbapenemas
type
carbapenemaseproduc
enterobacteriacea
cpe
caus
seriou
infect
immunocompromis
patient
associ
prolong
hospit
stay
increas
mortal
rate
panresist
antimicrobi
tzouveleki
et
al
klebsiella
pneumonia
carbapenemaseproduc
klebsiella
pneumonia
cpkp
emerg
immunosuppress
patient
expans
repres
challeng
problem
term
outcom
manag
retrospect
studi
girmenia
et
al
report
cpkp
document
allogen
hsct
italian
centr
colon
document
transplant
follow
infect
allogen
hsct
girmenia
et
al
analysi
case
kpc
bloodstream
infect
bsi
neutropen
patient
haematolog
malign
aplast
anaemia
conduct
tofa
et
al
report
episod
kpc
bsi
hospitalacquir
median
durat
hospit
onset
bacteraemia
day
cpkp
produc
kpc
enzym
produc
vim
enzym
tofa
et
al
pseudomona
aeruginosa
glucos
nonfer
gramneg
rod
strict
aerob
pathogen
cosmopolitan
distribut
particular
predilect
moist
environ
pseudomona
aeruginosa
shown
abil
acquir
resist
tradit
effect
agent
antipseudomon
penicillin
thirdand
fourthgener
cephalosporin
aminoglycosid
fluoroquinolon
carbapenem
patient
gastrointestin
colon
serv
import
reservoir
endogen
infect
well
sourc
horizont
transmiss
patient
patient
haematolog
malign
enter
colon
pseudomona
aeruginosa
occur
typic
chemotherapi
acinetobact
baumannii
nonfer
gramneg
pathogen
abil
surviv
dri
inanim
surfac
long
period
time
suggest
hospit
environ
serv
reservoir
mdr
strain
acinetobact
baumannii
resist
mani
avail
antibiot
multidrug
resist
common
us
hospitalacquir
infect
estim
colon
patient
skin
may
serv
effect
reservoir
healthcar
worker
hand
serv
vehicl
transmiss
commonli
employ
strategi
avoid
spread
acinetobact
baumannii
includ
identifi
elimin
common
sourc
contamin
optim
contact
isol
hand
hygien
minim
crosstransmiss
enhanc
environment
clean
reduc
contamin
reduc
broadspectrum
antibiot
use
lin
et
al
clostridium
difficil
anaerob
gramposit
sporeform
bacterium
increasingli
identifi
caus
nosocomi
diarrhoea
grow
number
patient
patient
admit
treatment
haematolog
malign
undergo
hsct
high
risk
clostridium
difficil
infect
cdi
risk
factor
cdi
includ
exposur
broadspectrum
antibiot
caus
chang
microbiota
gut
total
bodi
irradi
long
hospit
immunocompromis
state
older
age
irrit
intestin
mucosa
chemotherapi
drug
gu
et
al
adapt
debbi
weston
fundament
infect
prevent
control
event
confirm
clostridium
difficil
cd
toxinposit
result
patient
diarrhoea
alreadi
isol
patient
must
move
singl
room
en
suit
bathroom
dedic
night
commod
isol
notic
must
display
door
nurs
look
patient
inform
infect
prevent
control
team
isol
discontinu
patient
asymptomat
h
pass
normal
stool
dedic
patient
equip
must
use
includ
dispos
blood
pressur
cuff
tourniquet
floor
night
commod
toilet
bedfram
subject
heaviest
faecal
contamin
import
ward
environ
clutter
order
facilit
thorough
effect
ward
clean
discharg
transfer
patient
import
accur
clean
room
undertaken
use
ppm
avail
chlorin
andor
sporicid
agent
patient
assist
hand
hygien
use
toilet
night
commod
eat
unabl
wash
hand
independ
healthcar
worker
must
wash
hand
soap
water
contact
patient
hisher
environ
alcohol
hand
rub
gel
effect
clostridium
difficil
spore
wear
glove
apron
enter
patient
room
remov
apron
glove
leav
patient
room
hand
must
decontamin
put
remov
glove
ensur
healthcar
worker
visitor
wear
dispos
ppe
appropri
clinic
wast
linen
includ
bed
present
curtain
consid
contamin
manag
properli
patient
cd
transfer
ward
hospit
except
isol
purpos
requir
specialist
care
anoth
ward
patient
need
attend
depart
essenti
investig
nurs
look
patient
respons
inform
receiv
area
advanc
patient
cdposit
statu
possibl
symptomat
patient
seen
end
work
session
sent
depart
readi
see
avoid
leav
wait
area
patient
cd
spore
known
contamin
environ
resist
standard
disinfect
capabl
surviv
long
period
dri
surfac
bleach
solut
sporicid
use
environment
decontamin
outbreak
combin
strict
hand
hygien
contact
precaut
glove
apron
significantli
reduc
incid
cd
dubberk
riddl
firstlin
treatment
given
oral
metronidazol
mg
three
time
daili
day
andor
vancomycin
mg
everi
h
day
gu
et
al
report
treatment
berberin
cdi
first
symptom
appear
sever
case
cdi
studi
berberin
tradit
chines
medicin
use
treat
bacteri
secretori
diarrhoea
year
china
addit
studi
need
demonstr
whether
berberin
could
new
use
therapeut
agent
allevi
clinic
symptom
cdi
gu
et
al
treatment
recurr
cdi
fidaxomicin
probiot
intraven
immunoglobulin
faecal
transplant
treatment
faecal
microbiota
therapi
consist
techniqu
involv
transfer
fresh
stool
healthi
donor
gastrointestin
tract
patient
suffer
sever
recalcitr
clostridium
difficil
infect
cdi
case
report
neemann
et
al
donat
stool
sampl
screen
transmiss
pathogen
ova
parasit
clostridium
difficil
salmonella
shigella
campylobact
escherichia
coli
brief
liquefact
procedur
ml
fresh
stool
suspend
nonbacteriostat
salin
slowli
inject
via
nasojejun
tube
upper
jejunum
follow
nonbacteriostat
salin
flush
within
day
faecal
transplant
patient
diarrhoea
haematochezia
fulmin
cdi
unrespons
metronidazol
andor
vancomycin
definit
treatment
colectomi
faecal
microbiota
therapi
consid
potenti
boweland
lifesav
intervent
medic
modal
fail
neemann
et
al
anoth
case
report
castro
et
al
describ
persist
cdi
infect
diarrhoea
month
bone
marrow
transplant
patient
allerg
respons
oral
vancomycin
subsequ
treat
oral
metronidazol
iv
meropenem
perform
faecal
microbiota
transplant
materi
two
differ
donor
patient
bowel
show
signific
improv
antibiot
need
anymor
castro
et
al
haematopoiet
stem
cell
transplant
hsct
defin
transfer
haematopoiet
stem
cell
hsc
one
individu
anoth
allogen
hsct
return
previous
harvest
cell
individu
autolog
hsct
manipul
cell
recipi
tomblyn
et
al
haematopoiet
stem
cell
transplant
hsct
major
procedur
need
use
chemotherapi
patient
undergo
allogen
transplant
haematooncolog
malign
requir
radiotherapi
use
treatment
coupl
patient
diseas
compromis
immun
system
administr
immunosuppress
prevent
graft
reject
contribut
also
high
risk
infect
patient
group
brown
recent
year
improv
hsct
support
care
measur
better
understand
mechan
immunosuppress
introduct
reduc
intens
condit
ric
regimen
new
antiinfecti
agent
prophylact
strategi
decreas
infecti
morbid
mortal
howev
still
scope
improv
sinc
infect
remain
lead
caus
morbid
mortal
patient
undergo
hsct
gratwohl
et
al
statu
haematolog
diseas
hsct
comorbid
patient
degre
durat
neutropenia
disrupt
anatom
barrier
mucos
indwel
cathet
depress
tand
bcell
function
immunosuppress
therapi
type
transplant
autolog
allogen
sourc
progenitor
cell
bone
marrow
peripher
blood
cord
blood
condit
regimen
myeloabl
ric
nonmyeloabl
degre
histocompat
donor
recipi
sibl
unrel
mismatch
type
gvhd
prophylaxi
calcineurin
mtor
inhibitor
mono
polyclon
antibodi
tcell
deplet
presenc
grade
gvhd
treatment
depend
factor
patient
render
immunodefici
month
even
year
hsct
rovira
et
al
clear
relationship
type
immunodefici
hsct
incid
certain
infect
accord
three
differ
period
distinguish
predomin
specif
pathogen
phase
fig
tomblyn
et
al
rovira
et
al
chronolog
previous
mention
infect
describ
patient
receiv
myeloabl
hsct
differ
observ
recipi
autolog
hsct
richsct
thu
autolog
set
bacteri
infect
less
frequent
sever
infect
except
rovira
et
al
howev
autolog
candid
receiv
immunosuppress
agent
steroid
purin
analogu
monoclon
antibodi
rituximab
alemtuzumab
sever
hypogammaglobulinaemia
prior
autohsct
run
risk
develop
infect
patient
undergo
allogen
sct
past
two
decad
richsct
use
increasingli
worldwid
rovira
et
al
infect
relat
neutropenia
mucos
less
common
modal
hsct
convent
hsct
howev
viral
fungal
infect
occur
intermedi
late
period
compar
incid
sever
gvhd
similar
observ
myeloabl
hsct
addit
richsct
usual
use
older
patient
usual
poorer
gener
condit
without
presenc
comorbid
reason
infectionrel
mortal
decreas
set
rovira
et
al
masszi
mank
infect
major
caus
morbid
mortal
allogen
transplant
parodi
et
al
therefor
crucial
skill
nurs
team
assess
prevent
detect
treat
infect
delay
diagnos
infect
result
depress
inflammatori
respons
may
lead
increas
suscept
broad
rang
potenti
lifethreaten
organ
reason
addit
antimicrobi
prophylaxi
import
strategi
prevent
infect
exampl
build
multiprofession
network
team
special
infect
control
measur
masszi
mank
larg
number
patient
consid
risk
requir
evalu
propos
protect
system
relat
effect
applic
cost
benefit
pizzo
centr
diseas
control
prevent
cdc
publish
specif
recommend
regard
precaut
taken
haematopoiet
stem
cell
transplant
hsct
report
updat
cdc
recommend
protect
isol
patient
undergo
allogen
hsct
indic
use
singl
room
use
filter
air
enter
central
portabl
higheffici
filter
hepa
capabl
remov
um
diamet
particl
autolog
hsct
specif
indic
refer
standard
precaut
shown
tabl
interact
patient
protect
lab
standard
precaut
set
infect
control
practic
use
prevent
transmiss
diseas
acquir
contact
blood
bodi
fluid
nonintact
skin
includ
rash
mucou
membran
measur
use
provid
care
individu
whether
appear
infecti
symptomat
hand
hygien
hand
hygien
refer
wash
plain
antibacteri
soap
water
use
alcohol
gel
decontamin
hand
hand
visibl
soil
alcohol
gel
prefer
method
hand
hygien
provid
healthcar
client
person
protect
equip
ppe
ppe
includ
item
glove
gown
mask
respir
eyewear
protector
use
creat
barrier
protect
skin
cloth
mucou
membran
respiratori
tract
infecti
agent
ppe
use
last
resort
work
practic
engin
control
alon
elimin
worker
exposur
item
select
use
depend
type
interact
public
health
worker
client
like
mode
diseas
transmiss
wear
glove
touch
blood
bodi
fluid
nonintact
skin
mucou
membran
contamin
item
glove
must
alway
worn
activ
involv
vascular
access
perform
phlebotomi
wear
surgic
mask
goggl
face
shield
reason
chanc
splash
spray
blood
bodi
fluid
may
occur
eye
mouth
nose
wear
gown
skin
cloth
like
expos
blood
bodi
fluid
remov
ppe
immedi
use
wash
hand
import
remov
ppe
proper
order
prevent
contamin
skin
cloth
needl
stick
sharp
injuri
prevent
safe
handl
needl
sharp
devic
compon
standard
precaut
implement
prevent
healthcar
worker
exposur
bloodborn
pathogen
needlestick
safeti
prevent
act
link
extern
mandat
use
sharp
engin
safeti
devic
suitabl
devic
exit
clean
disinfect
client
care
area
common
wait
area
area
client
may
potenti
contamin
surfac
object
frequent
touch
staff
client
doorknob
sink
toilet
surfac
item
close
proxim
client
clean
routin
eparegist
disinfect
follow
manufactur
instruct
amount
dilut
contact
time
continu
coat
glove
mask
indic
absenc
suspect
confirm
infect
patient
tomblyn
et
al
effect
specif
precaut
prevent
infect
patient
undergo
autolog
hsct
evalu
must
follow
standard
precaut
everi
patient
contact
centr
use
addit
protect
effort
reduc
risk
infect
insuffici
data
recommend
behaviour
tomblyn
et
al
consist
organ
depart
would
advis
hospit
patient
singl
room
attach
bathroom
order
give
greater
comfort
ventil
system
ensur
least
air
chang
per
hour
direct
flow
area
room
must
way
opposit
side
respect
entri
optimum
ambient
air
qualiti
obtain
without
use
expens
laminar
flow
room
hous
highli
immunocompromis
patient
need
place
posit
pressur
prevent
entri
room
airborn
pathogen
hallway
adjac
space
room
forbidden
keep
fresh
flower
andor
dri
pot
plant
tomblyn
et
al
although
unlik
exposur
plant
caus
invas
fungal
infect
patient
undergo
hsct
recommend
plant
dri
fresh
flower
enter
room
hospit
condit
phase
includ
aspergillu
sp
isol
soil
ornament
plant
flower
addit
found
high
proport
gramneg
bacteria
water
cut
flower
vase
pseudomona
tomblyn
et
al
patient
hospit
protect
environ
exit
room
restrict
execut
diagnost
test
short
period
construct
site
present
nearbi
hospit
indic
use
filter
mask
prevent
inhal
spore
recommend
regard
use
mask
filter
absenc
construct
work
tomblyn
et
al
import
point
prevent
infect
hospit
patient
protect
isol
remain
handwash
hand
hygien
key
element
standard
precaut
type
patient
tomblyn
et
al
client
wait
room
common
area
spread
infect
other
area
local
public
health
agenc
staff
measur
avoid
spread
respiratori
secret
promot
help
prevent
respiratori
diseas
transmiss
element
respiratori
hygien
cough
etiquett
includ
cover
nosemouth
tissu
cough
sneez
use
crook
elbow
contain
respiratori
droplet
use
tissu
contain
respiratori
secret
discard
nearest
wast
receptacl
use
perform
hand
hygien
handwash
nonantimicrobi
soap
water
alcoholbas
hand
rub
antisept
handwash
immedi
contact
respiratori
secret
contamin
objectsmateri
ask
client
sign
symptom
respiratori
ill
wear
surgic
mask
whilst
wait
common
area
place
immedi
examin
room
area
away
other
provid
tissu
notouch
receptacl
use
tissu
dispos
space
seat
wait
area
least
three
feet
apart
minim
close
contact
among
person
area
suppli
tissu
wastebasket
alcohol
gel
surgic
mask
provid
wait
common
area
local
public
health
agenc
place
cough
etiquett
sign
link
extern
gener
public
see
wast
dispos
safe
inject
practic
outbreak
hepat
b
hepat
c
infect
us
ambulatori
care
facil
prompt
need
reemphas
safe
inject
practic
healthcar
personnel
give
inject
strictli
adher
cdc
recommend
staff
visitor
must
wash
hand
enter
patient
room
order
reduc
risk
cross
infect
hand
hygien
perform
touch
patient
cleanasept
procedur
bodi
fluid
exposur
risk
blood
bodi
fluid
excret
mucou
membran
nonintact
skin
dress
touch
patient
touch
patient
surround
five
moment
hand
hygien
also
advis
wear
fals
nail
extens
direct
contact
patient
maintain
natur
nail
short
even
still
unsolv
problem
mani
studi
shown
skin
ring
colon
without
ring
dirti
jewelri
host
microorgan
furthermor
hand
hygien
done
perfect
way
wear
bulki
ring
expert
recommend
strongli
discourag
use
ring
assist
guidelin
nurs
import
role
educ
famili
patient
visitor
effect
handwash
shown
fig
provid
relev
inform
reduc
risk
contract
infect
transplant
centr
display
cartoon
near
sink
entranc
hospit
room
describ
handwash
procedur
step
step
need
perform
guidelin
environment
clean
play
import
role
prevent
nosocomi
infect
particularli
patient
haematolog
cancer
diseas
undergo
transplant
haematopoiet
stem
cell
clean
staff
must
well
prepar
need
inform
train
particular
attent
problem
immunosuppress
patient
prefer
assign
stabl
staff
divis
order
ensur
continu
servic
hospit
room
must
clean
day
special
dust
control
must
remov
damp
light
fixtur
outdoor
grill
ventil
vent
horizont
surfac
clean
premoisten
dispos
cloth
disinfect
fda
environment
protect
agenc
approv
design
select
furnitur
transplant
program
focus
creat
maintain
environ
free
dust
floor
finish
brushabl
waterproof
easi
disinfect
antistat
tomblyn
et
al
verifi
hospit
room
effect
reduc
environment
load
period
monitor
environ
must
guarante
linen
chang
daili
pillow
mattress
protect
coat
hospit
stay
patient
undergo
hsct
enough
wash
cloth
linen
high
temperatur
wash
machin
tomblyn
et
al
centr
polici
number
visitor
allow
frequenc
visit
howev
centr
agreement
point
come
contact
patient
cool
suffer
infect
rash
eye
infect
nausea
andor
vomit
recent
exposur
exanthemat
diseas
chickenpox
measl
tomblyn
et
al
person
hygien
key
aspect
patient
undergo
hsct
repres
effect
way
reduc
infect
caus
endogen
organ
interview
patient
famili
import
moment
must
program
hsct
nurs
must
abl
defin
major
need
patient
import
explain
import
person
hygien
role
prevent
infect
sever
centr
support
audiovisu
media
inform
booklet
reinforc
provid
inform
nurs
give
precis
indic
must
abl
explain
thought
sensit
incid
person
hygien
individu
intim
person
sphere
tabl
show
recommend
panel
expert
cdc
carrera
cdc
oral
gastrointestin
mucos
caus
highdos
chemotherapi
andor
radiat
continu
import
clinic
problem
incid
grade
oral
mucos
high
patient
undergo
hsct
depend
intens
condit
regimen
use
prophylact
use
methotrex
prevent
graft
versu
host
diseas
manag
oral
gastrointestin
mucos
one
main
challeng
period
aplasia
risk
sepsi
relat
degre
mucos
barrier
breakdown
depth
marrow
suppress
peterson
et
al
oral
care
import
aspect
control
infect
transplant
patient
quinn
et
al
order
improv
oral
care
patient
undergo
chemotherapyhsct
use
build
multiprofession
team
includ
medic
dental
nurs
nutrit
physic
therapi
counsel
provid
train
continu
educ
program
ensur
knowledg
spread
extens
commun
healthcar
provid
make
posit
impact
patient
healthcar
sharon
elad
et
al
treatment
strategi
aim
improv
mouth
care
depend
four
key
principl
accur
assess
oral
caviti
individu
plan
care
time
prevent
measur
correct
treatment
initi
quinn
et
al
use
central
venou
cathet
cvc
link
need
infus
complex
therapi
long
time
avail
valid
secur
access
gener
choic
appropri
cathet
share
multidisciplinari
team
take
account
patient
complianc
therapeut
process
hesh
face
goal
care
cvc
manag
must
aim
ensur
prevent
infect
mainten
patenc
feasibl
devic
manag
compet
healthcar
materi
toilet
must
new
close
pack
dri
peel
skin
may
use
appli
moistur
bodi
hospit
period
follow
product
use
soap
perfum
deodor
aftershav
contain
alcohol
cotton
stick
ear
clean
patient
clean
extern
pinna
soap
water
lipstick
patient
advis
cut
nail
hand
feet
admiss
aplasia
suscept
infect
bleed
also
keep
short
nail
facilit
good
hand
hygien
enamel
fals
nail
remov
thorough
person
hygien
allow
patient
evalu
daili
state
hisher
skin
promptli
notifi
physician
nurs
staff
chang
erythema
desquam
haematoma
men
electr
razor
recommend
razor
blade
scissor
forbidden
due
increas
bleed
risk
worker
process
base
continu
improv
perform
rcn
in
cdc
import
recommend
concern
prevent
cvcrelat
bloodstream
infect
hand
hygien
maximum
barrier
precaut
low
bacteri
diet
lbd
also
known
neutropen
diet
low
microbi
diet
diet
aim
reduc
ingest
bacteri
fungal
contamin
exclud
food
fresh
fruit
veget
raw
egg
raw
meat
fish
unpasteur
dairi
product
ice
yogurt
exclud
type
diet
raw
food
contain
probiot
consumpt
fruit
thick
skin
peel
wash
accord
good
hygien
practic
low
probabl
contamin
todd
et
al
decad
concept
neutropen
diet
diet
contain
food
low
level
bacteria
lbd
impli
strict
limit
food
allow
consumpt
presumpt
mean
reduc
risk
infect
cancer
patient
rational
limit
introduct
potenti
harm
bacteria
gastrointestin
tract
restrict
certain
food
might
harbour
organ
fox
freifeld
howev
clear
evid
use
low
bacteri
diet
lbd
actual
decreas
number
infect
clear
numer
survey
current
practic
major
hospit
place
neutropen
patient
restrict
diet
mank
et
al
mani
studi
limit
conclud
differ
term
infecti
episod
surviv
compar
normal
neutropen
diet
van
tiel
et
al
gardner
et
al
trifilio
et
al
random
studi
patient
acut
myeloid
leukaemia
undergo
induct
therapi
differ
term
infecti
episod
surviv
report
patient
prescrib
lbd
put
normal
diet
conclus
lbd
prevent
major
infect
death
gardner
et
al
notabl
studi
use
nonneutropen
diet
show
increas
satisfact
meal
maximum
feedback
team
posit
tarr
allen
patient
prescrib
neutropen
diet
may
poor
nutrit
statu
often
need
counsel
nutrit
support
murray
pindoria
studi
conduct
brazil
show
dietari
restrict
lead
defici
vitamin
c
galati
et
al
retrospect
studi
patient
undergo
hct
show
rate
acut
grade
iiiv
gi
gvhd
higher
neutropen
diet
nd
group
although
differ
group
reach
statist
signific
associ
gvhd
nd
report
previous
almost
onehalf
patient
nd
group
subsequ
develop
gvhd
previou
c
difficil
infect
nonrelaps
mortal
high
group
nutrit
support
guidelin
patient
gi
gvhd
also
common
sens
includ
low
microbi
diet
trifilio
et
al
studi
result
line
preclin
experi
conduct
mice
presenc
mix
intestin
flora
eg
lactobacillu
rhamnosu
gg
would
abl
decreas
prolifer
virul
bacteri
speci
system
immunomodul
intestin
docampo
et
al
liber
diet
could
bring
benefit
term
palat
cholesterol
reduc
use
parenter
nutrit
improv
qualiti
life
lbd
usual
poorer
nutrit
point
view
less
attract
compar
normal
diet
may
unnecessari
burden
patient
alreadi
difficulti
eat
studi
review
support
signific
result
effect
ineffect
ldb
mani
use
result
still
encourag
use
lbd
protect
isol
signific
psycholog
effect
patient
patient
encourag
person
room
famili
pictur
may
comput
access
abl
maintain
commun
famili
member
friend
way
howev
length
time
spent
isol
lead
mani
patient
feel
anxieti
fear
futur
concern
famili
worri
whether
engraft
occur
brown
need
regular
monitor
blood
constant
remind
patient
situat
loss
bodi
imag
result
weight
loss
scar
sexual
issu
concern
employ
may
preoccupi
patient
gruber
et
al
nurs
awar
potenti
effect
transplant
isol
patient
spend
time
patient
offer
opportun
talk
concern
help
provid
inform
educ
advic
may
reduc
neg
psycholog
effect
isol
brown
howev
consid
select
categori
patient
possibl
earli
discharg
transplant
provid
comfort
environ
patient
famili
increas
implement
ambulatori
treatment
potenti
decreas
patient
exposur
multidrugresist
organ
hospit
provid
patient
possibl
spend
neutropen
phase
home
facilit
admiss
haematolog
ward
mank
et
al
discharg
much
desir
patient
difficult
time
cours
treatment
patient
famili
face
everyday
life
far
safe
hospit
environ
fact
hospit
continu
support
multidisciplinari
team
make
feel
protect
hospit
doctor
nurs
profession
alway
present
clarifi
doubt
give
advic
also
tri
reduc
anxieti
fear
awar
risk
infect
mean
go
home
stress
brown
nurs
spend
time
patient
identifi
explor
concern
discharg
case
patient
may
becom
overdepend
nurs
staff
may
need
address
allogen
transplant
patient
high
risk
readmiss
result
infect
critic
discharg
plan
provid
patient
understand
inform
best
minim
risk
infect
grant
et
al
checklist
inform
patient
receiv
discharg
provid
tabl
patient
advis
continu
oral
care
routin
import
reiter
patient
handwash
carri
particularli
eat
meal
prepar
handl
pet
sneez
cough
take
oral
tablet
touch
soil
linen
go
outdoor
brown
patient
requir
great
deal
inform
discharg
would
includ
inform
followup
treatment
recent
research
suggest
pulmonari
complic
lead
caus
posttranspl
complic
death
hsct
recipi
alsharif
roychowdhuri
et
al
posttranspl
pulmonari
complic
classifi
either
infecti
noninfecti
rate
complic
significantli
lower
autolog
transplant
recipi
allogen
transplant
recipi
absent
risk
gvhd
autolog
transplant
infrequ
use
immunosuppress
medic
ciclosporin
tacrolimu
absenc
radiat
therapi
precondit
regimen
ho
et
al
kotloff
et
al
method
healthcar
profession
use
improv
patient
outcom
autolog
allogen
recipi
includ
rais
clinic
awar
improv
diagnost
shorten
time
medic
intervent
continu
multidisciplinari
research
stephen
et
al
spectrum
pulmonari
complic
transplant
recipi
continu
chang
due
part
rapid
advanc
support
care
increas
age
transplant
recipi
new
antivir
antifung
agent
increas
use
prophylact
broadspectrum
antibiot
posttranspl
sharma
et
al
real
key
howev
decreas
morbid
mortal
adult
paediatr
hsct
patient
popul
remain
effect
diagnost
techniqu
stephen
et
al
pulmonari
infect
largest
caus
posthsct
infect
morbid
report
recipi
carri
mortal
rate
cook
et
al
zuccotti
et
al
princip
caus
infect
sever
immunocompromis
statu
patient
diseas
process
malign
nonmalign
condit
regimen
nonmyeloabl
myeloabl
immunosuppress
prophylaxi
prevent
treat
gvhd
ct
studi
escuissato
et
al
found
viral
infect
common
posttranspl
recipi
follow
bacteri
infect
fungal
infect
protozo
infect
less
case
examin
patient
two
infecti
agent
concurr
complic
follow
stem
cell
transplant
tabl
diagnost
techniqu
pulmonari
diseas
hsct
patient
similar
non
transplant
patient
chest
radiograph
xray
thorac
comput
tomographi
ct
scan
remain
popular
less
invas
option
ct
scan
particularli
use
compar
twodimension
xray
expos
acut
chronic
chang
lung
parenchyma
respiratori
ct
scan
involv
take
pictur
crosssect
lung
tissu
use
high
specialfrequ
reconstruct
inhal
exhal
stephen
et
al
chang
nodul
white
glassi
appear
signal
physician
radiolog
staff
consid
addit
diagnost
truong
et
al
could
includ
collect
sputum
sampl
bronchoscopi
without
bronchoalveolar
lavag
bal
open
lung
tabl
typic
onset
pulmonari
complic
follow
stem
cell
transplant
divid
three
stage
base
inform
antin
raley
camu
costabel
coom
et
al
polovich
et
al
soubani
pandya
kaplan
et
al
truong
et
al
sputum
sampl
collect
nurs
physician
respiratori
therapist
accord
transplant
program
protocol
respiratori
viru
detect
highli
depend
type
sampl
collect
time
collect
onset
clinic
symptom
age
patient
transport
storag
sampl
prior
test
sever
differ
upper
respiratori
tract
specimen
applic
test
includ
nasopharyng
np
wash
np
aspir
np
swab
place
viru
transport
media
specter
storch
expector
earli
morn
respiratori
procedur
easiest
patient
produc
natur
accumul
secret
time
ml
sputum
usual
requir
adequ
laboratori
analysi
recent
studi
suggest
sputum
must
reach
laboratori
within
hour
expector
murray
et
al
sputum
also
collect
bronchoscopi
case
broncholveolar
lavag
bal
perform
bronchoscopi
bal
involv
flush
fluid
usual
steril
normal
salin
solut
local
area
lower
respiratori
tract
immedi
suction
fluid
bronchoscop
steril
specimen
contain
bal
allow
detect
character
sever
respiratori
pathogen
includ
viral
fungal
bacteri
agent
consid
major
diagnost
mechan
pneumocysti
carinii
call
pneumocysti
jirovecii
pneumonia
pcp
et
al
patient
focal
pulmonari
lesion
aspergillosi
pulmonari
gvhd
fineneedl
aspir
biopsi
consid
firstlin
diagnost
method
gupta
et
al
commonli
occur
first
month
occur
time
gramneg
gramposit
organ
caus
pneumonia
common
escherichia
coli
klebsiella
pseudomona
enterobact
acinetobact
staphylococcu
aureu
coagulaseneg
staphylococcu
streptococcu
pneumonia
streptococcu
viridan
enterococcu
one
also
need
recogn
risk
mycoplasma
chlamydia
infect
although
common
use
fluoroquinolon
empir
treat
organ
caus
late
pneumonia
miss
includ
nocardia
listeria
actinomyc
includ
cmv
herp
simplex
viru
hsv
varicella
zoster
viru
vzv
adenoviru
respiratori
syncyti
viru
rsv
influenza
parainfluenza
type
iii
metapneumoviru
varieti
respiratori
pathogen
noncmv
viral
infect
may
occur
earlier
day
later
transplant
cours
cmv
typic
occur
day
earli
detect
cmv
advanc
treatment
reduc
diseas
mortal
associ
cmv
diseas
vzv
lead
pneumonia
without
classic
vesicular
rash
hsvvzv
prophylaxi
initi
condit
regimen
continu
year
patient
immunosuppress
agent
number
restor
communityacquir
viral
infect
lethal
especi
parainfluenza
type
iii
sinc
except
influenza
effect
therapi
best
approach
prevent
isol
diagnosi
base
fever
cough
sign
symptom
uri
nasal
wash
viral
swab
pcr
invas
fungal
diseas
major
obstacl
patient
transplant
major
caus
pulmonaryrel
mortal
ji
et
al
aspergillu
common
virul
fungal
caus
pneumonia
follow
hsct
blae
et
al
wilson
et
al
fungal
respiratori
infect
posthsct
patient
particularli
receiv
myeloabl
condit
includ
malassezia
zygomycet
candida
speci
wilson
et
al
past
decad
sever
new
antifung
medic
demonstr
increas
success
show
improv
remiss
rate
therebi
decreas
morbid
fever
pleurit
chest
discomfort
dyspnoea
imag
show
nodul
cavit
infiltr
classic
halo
sign
may
seen
chest
ct
imag
may
help
bal
may
use
galactomannan
betaglucan
test
may
help
alway
inform
pneumocysti
jirovecii
pneumonia
risk
pneumocysti
jirovecii
pneumonia
pcp
start
around
day
effect
administ
prophylaxi
elimin
pcp
fever
cough
hypoxemia
posit
bal
cxr
bilater
groundglass
infiltr
betaglucan
typic
detect
histori
noncompli
prophylaxi
medic
elicit
typic
involv
brain
heart
lung
biopsi
sampl
giemsa
stain
confirm
diagnosi
test
purifi
protein
deriv
ppd
often
help
allogen
stem
cell
transplant
depress
delayedtyp
hypersensit
reaction
therefor
skin
reaction
ppd
like
occur
cultur
sputum
sampleb
variou
indirect
assay
quantiferon
gold
help
patient
undergo
hsct
risk
pulmonari
complic
bedsid
nurs
like
observ
subtl
chang
patient
condit
reason
critic
nurs
staff
work
hsct
popul
highli
train
oncolog
critic
care
intervent
prompt
report
symptom
ensur
proper
time
medic
intervent
facilit
improv
patient
outcom
found
particularli
true
identifi
gvhd
clinic
nurs
forefront
identifi
report
suspici
symptom
healthcar
team
mattson
nurs
take
central
role
patient
famili
educ
regard
cours
treatment
complic
key
piec
hsct
process
includ
care
central
line
stephen
et
al
educ
patient
expect
transplant
regard
troubl
symptom
nurs
ensur
patient
particip
identifi
develop
complic
earli
improv
hsct
outcom
thorough
assess
assist
nurs
staff
detect
chang
indic
develop
complic
vital
sign
includ
rate
qualiti
respir
oximetri
perform
per
program
protocol
usual
everi
h
frequent
patient
risk
pulmonari
insuffici
take
patient
temperatur
everi
h
necessari
anoth
critic
respiratori
intervent
posthsct
complic
infecti
natur
stephen
et
al
nurs
crucial
assess
patient
symptom
bacteri
infect
perform
routin
laboratori
test
necessari
regard
pulmonari
infect
nurs
close
monitor
patient
symptom
progress
respiratori
diseas
decreas
auscult
air
sound
lung
increas
fever
appear
product
cough
colour
sputum
antibiot
start
soon
possibl
patient
nurs
studi
neutropen
patient
earli
hsct
phase
show
commenc
antibiot
within
h
onset
infecti
symptom
significantli
reduc
infecti
complic
includ
sepsi
hyman
recent
addit
monoclon
antibodi
moab
gvhd
prophylaxi
protocol
met
mix
result
exampl
studi
use
infliximab
lead
lower
rate
gvhd
suggest
higher
rate
bacteri
fungal
pulmonari
infect
patient
particip
studi
hamadani
et
al
import
patient
posttranspl
period
encourag
pace
activ
level
abil
cough
deep
breath
exercis
accompani
regular
use
incent
spiromet
constitut
critic
way
open
deep
alveolar
tissu
encourag
pulmonari
toilet
patient
prone
fatigu
malais
whose
blood
count
low
stephen
et
al
primari
immunodefici
patient
immun
live
viral
bacteri
vaccin
known
hazard
patient
seriou
immunodefici
shearer
et
al
protect
immun
respons
therefor
risk
develop
diseas
marciano
et
al
avoid
immun
live
bacillu
calmetteguerin
bcg
rotaviru
vaccin
live
polioviru
sinc
caus
persist
dissemin
infect
shearer
et
al
river
gaspar
patient
scid
receiv
bcg
vaccin
prior
diagnosi
need
start
antituberculosi
treatment
river
gaspar
patient
receiv
bcg
vaccin
prior
diagnosi
need
start
antituberculosi
treatment
bcg
vaccin
given
infant
sever
primari
immun
defici
develop
bcgiti
character
local
erythema
purul
region
lymph
node
enlarg
bcgosi
sever
form
dissemin
infect
could
fatal
involv
distant
lymph
node
bone
liver
spleen
shrot
et
al
open
access
chapter
licens
term
creativ
common
attribut
intern
licens
http
permit
use
share
adapt
distribut
reproduct
medium
format
long
give
appropri
credit
origin
author
sourc
provid
link
creativ
common
licens
indic
chang
made
imag
third
parti
materi
chapter
includ
chapter
creativ
common
licens
unless
indic
otherwis
credit
line
materi
materi
includ
chapter
creativ
common
licens
intend
use
permit
statutori
regul
exce
permit
use
need
obtain
permiss
directli
copyright
holder
